These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30517530)

  • 1. Favorable responses to treatment with 5 mg Sbv/kg/day meglumine antimoniate in patients with American tegumentary leishmaniasis acquired in different Brazilian regions.
    Cataldo JI; Conceição-Silva F; Antônio LF; Schubach AO; Marzochi MCA; Valete-Rosalino CM; Pimentel MIF; Lyra MR; Oliveira RVC; Barros JHDS; Pacheco RDS; Madeira MF
    Rev Soc Bras Med Trop; 2018; 51(6):769-780. PubMed ID: 30517530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. American tegumentary leishmaniasis in Brazil: a critical review of the current therapeutic approach with systemic meglumine antimoniate and short-term possibilities for an alternative treatment.
    Carvalho SH; Frézard F; Pereira NP; Moura AS; Ramos LMQC; Carvalho GB; Rocha MOC
    Trop Med Int Health; 2019 Apr; 24(4):380-391. PubMed ID: 30681239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low dose systemic or intralesional meglumine antimoniate treatment for American tegumentary leishmaniasis results in low lethality, low incidence of relapse, and low late mucosal involvement in a referral centre in Rio de Janeiro, Brazil (2001-2013).
    Brahim LR; Valete-Rosalino CM; Antônio LF; Pimentel MIF; Lyra MR; Paes LEC; Costa ADD; Vieira IF; Dias CMG; Duque MCO; Marzochi MCA; Schubach AO
    Mem Inst Oswaldo Cruz; 2017 Dec; 112(12):838-843. PubMed ID: 29211245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotypic profiles of Leishmania (Viannia) braziliensis strains from cutaneous leishmaniasis patients and their relationship with the response to meglumine antimoniate treatment: a pilot study.
    Gagini T; de Oliveira Schubach A; de Fatima Madeira M; Maria Valete-Rosalino C; Fernandes Pimentel MI; da Silva Pacheco R
    Parasite; 2017; 24():34. PubMed ID: 28959938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between systemic and intralesional meglumine antimoniate therapy in a primary health care unit.
    de Oliveira Duque MC; Quintão Silva JJ; Soares PAO; Magalhães RS; Horta APA; Paes LRB; Rosandiski Lyra M; Pimentel MIF; de Fátima Antonio L; de Camargo Ferreira E Vasconcellos É; Saheki MN; de Almeida Marzochi MC; Valete-Rosalino CM; de Oliveira Schubach A
    Acta Trop; 2019 May; 193():176-182. PubMed ID: 30851256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An old drug and different ways to treat cutaneous leishmaniasis: Intralesional and intramuscular meglumine antimoniate in a reference center, Rio de Janeiro, Brazil.
    Oliveira-Ribeiro C; Pimentel MIF; Oliveira LFA; Vasconcellos ÉCFE; Conceição-Silva F; Schubach AO; Fagundes A; de Mello CX; Mouta-Confort E; Miranda LFC; Valete-Rosalino CM; Martins ACDC; Oliveira RVC; Quintella LP; Lyra MR
    PLoS Negl Trop Dis; 2021 Sep; 15(9):e0009734. PubMed ID: 34555016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intralesional meglumine antimoniate for treatment of cutaneous leishmaniasis patients with contraindication to systemic therapy from Rio de Janeiro (2000 to 2006).
    Vasconcellos Ede C; Pimentel MI; Schubach Ade O; de Oliveira Rde V; Azeredo-Coutinho RB; Silva Fda C; Salgueiro Mde M; Moreira JS; Madeira Mde F; Baptista C; Valete-Rosalino CM
    Am J Trop Med Hyg; 2012 Aug; 87(2):257-60. PubMed ID: 22855754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Self-reporting of hearing loss and tinnitus in the diagnosis of ototoxicity by meglumine antimoniate in patients treated for American tegumentary Leishmaniasis.
    Duarte CCJ; Torraca TSS; Bezerra DO; Oliveira RB; Leite NKS; de Oliveira RVC; Araújo-Melo MH; Pimentel MIF; Costa ADD; Vasconcellos ÉCF; Lyra MR; Soares ECDA; Paes LRDNB; Salgueiro MM; Schubach AO; Valete CM
    PLoS One; 2024; 19(2):e0296728. PubMed ID: 38354178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associated-risk determinants for anthroponotic cutaneous leishmaniasis treated with meglumine antimoniate: A cohort study in Iran.
    Aflatoonian MR; Sharifi I; Aflatoonian B; Bamorovat M; Heshmatkhah A; Babaei Z; Ghasemi Nejad Almani P; Mohammadi MA; Salarkia E; Aghaei Afshar A; Sharifi H; Sharifi F; Khosravi A; Khatami M; Arefinia N; Fekri A; Farajzadeh S; Khamesipour A; Mohebali M; Gouya MM; Shirzadi MR; Varma RS
    PLoS Negl Trop Dis; 2019 Jun; 13(6):e0007423. PubMed ID: 31188834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meglumine antimoniate is more effective than sodium stibogluconate in the treatment of cutaneous leishmaniasis.
    Yesilova Y; Surucu HA; Ardic N; Aksoy M; Yesilova A; Oghumu S; Satoskar AR
    J Dermatolog Treat; 2016; 27(1):83-7. PubMed ID: 26105204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review.
    Brito NC; Rabello A; Cota GF
    PLoS One; 2017; 12(9):e0184777. PubMed ID: 28926630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized, Controlled, Noninferiority, Multicenter Trial of Systemic vs Intralesional Treatment With Meglumine Antimoniate for Cutaneous Leishmaniasis in Brazil.
    Lyra MR; Oliveira LFA; Schubach AO; Sampaio RNR; Rodrigues BC; Hueb M; Cota G; Silva RE; Francesconi F; Pompilio MA; França AO; Amato VS; Souza RM; Oliveira RVC; Valete CM; Pimentel MIF
    Clin Infect Dis; 2023 Aug; 77(4):574-582. PubMed ID: 37100061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.
    Nilforoushzadeh MA; Jaffary F; Ansari N; Siadat AH; Nilforoushan Z; Firouz A
    J Vector Borne Dis; 2008 Dec; 45(4):287-91. PubMed ID: 19248655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intralesional infiltration versus parenteral use of meglumine antimoniate for treatment of cutaneous leishmaniasis: A cost-effectiveness analysis.
    Brito NC; Machado de Assis TS; Rabello A; Cota G
    PLoS Negl Trop Dis; 2019 Dec; 13(12):e0007856. PubMed ID: 31805052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen and meglumine antimoniate combined therapy in cutaneous leishmaniasis patients: a randomised trial.
    Machado PRL; Ribeiro CS; França-Costa J; Dourado MEF; Trinconi CT; Yokoyama-Yasunaka JKU; Malta-Santos H; Borges VM; Carvalho EM; Uliana SRB
    Trop Med Int Health; 2018 Sep; 23(9):936-942. PubMed ID: 29924907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of miltefosine with granulocyte and macrophage colony-stimulating factor (GM-CSF) in the treatment of cutaneous leishmaniasis in the Amazon region: A randomized and controlled trial.
    Mendes L; Guerra JO; Costa B; Silva ASD; Guerra MDGB; Ortiz J; Doria SS; Silva GVD; de Jesus DV; Barral-Netto M; Penna G; Carvalho EM; Machado PRL
    Int J Infect Dis; 2021 Feb; 103():358-363. PubMed ID: 33253864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meglumine antimoniate was associated with a higher cure rate than liposomal amphotericin B in the treatment of American tegumentary leishmaniasis: A retrospective cohort study from a
    Barroso DH; Gonçalves RT; Barbosa JS; da Motta JOC; Freire GSM; Gomes CM; Sampaio RNR
    Front Cell Infect Microbiol; 2022; 12():993338. PubMed ID: 36211958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The activity of encapsulated meglumine antimoniate in stearylamine-bearing liposomes against cutaneous leishmaniasis in BALB/c mice.
    Moosavian SA; Fallah M; Jaafari MR
    Exp Parasitol; 2019 May; 200():30-35. PubMed ID: 30898544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate: A case series.
    Arboleda M; Barrantes S; Úsuga LY; Robledo SM
    Rev Soc Bras Med Trop; 2019 May; 52():e20180211. PubMed ID: 31141044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should we continue to indicate meglumine antimoniate as first-line treatment for cutaneous leishmaniasis in Tunisia.
    Mlika RB; Hamida MB; Hammami H; Jannet SB; Badri T; Fenniche S; Mokhtar I
    Dermatol Ther; 2012; 25(6):615-8. PubMed ID: 23210761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.